Becaplermin
Top View
- 2021 California Advantage Large Group 3-Tier HMO and PPO Prescription Drug List
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- Long-Term Care Drug Database System: Drugs by NDC Class Code, Drug Code and Name
- Medicines Regulations 1984 (SR 1984/143)
- Growth Factors for Treating Diabetic Foot Ulcers (Review)
- Regranex Label
- Physician-Initiated Clinical Study of Limb Ulcers Treated with a Functional Peptide, SR-0379: from Discovery to a Randomized, Double-Blind, Placebo-Controlled Trial
- Drug Coverage Guidelines – Oxford Clinical Policy
- (PA) Cross Reference
- Effects of Topical Application of CHF6467, a Mutated Form of Human Nerve Growth Factor, on Skin Wound Healing in Diabetic Mice
- September 2021 California Advantage Large Group 3-Tier PPO Prescription Drug List – CDI Version
- Cutaneous Wound Healing: an Update from Physiopathology to Current Therapies
- Becaplermin Gel (Regranex®)
- Oregon Medicaid Fee-For-Service
- Becaplermin Gel in the Treatment of Diabetic Neuropathic Foot Ulcers
- WO 2014/165513 A2 9 October 2014 (09.10.2014) P O P C T
- Recombinant and Autologous Platelet Derived Growth Factors As Tx of Wound Healing and Other Non-Orthopedic Conditions
- Regranex) Reference Number: CP.PMN.21 Effective Date: 09.01.06 Last Review Date: 02.21 Line of Business: Medicaid Revision Log